Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)

Update: 2025-11-18

Description

Dr. Aaron Zelikovich discusses a recent article on nipocalimab and its role in treating generalized myasthenia gravis.

Show citations:

Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. doi:10.1016/S1474-4422(24)00498-8

Comments

In Channel

Primary Progressive Aphasia - Part 3

2025-12-0101:41

Screening for Congenital Myasthenic Syndromes in Adults With Seronegative MG

2025-11-2802:11

Executive Function Deficits in Genetic Frontotemporal Dementia

2025-11-2701:45

Primary Progressive Aphasia - Part 2

2025-11-2601:23

Primary Progressive Aphasia - Part 1

2025-11-2502:08

Women History Minute - Sylvia Lawry

2025-11-2405:18

Dementia with Lewy Bodies and Parkinson Disease Dementia

2025-11-2102:11

Outcomes After RCVS With Convexity Subarachnoid Hemorrhage

2025-11-2003:32

November President Spotlight: Medicare 2026 Rulemaking

2025-11-1904:09

Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)

2025-11-1803:05

Interpreting Cerebrospinal Fluid in the 2024 McDonald Criteria Revisions

2025-11-1702:27

Women History Minute - Marcelle Lapicque

2025-11-1404:14

$Super Refractory Status Epilepticus Diagnosis, Management, and Prognostication$

Super Refractory Status Epilepticus Diagnosis, Management, and Prognostication

2025-11-1304:38

Prodromal Phase of Migraine - Part 2

2025-11-1202:56

Prodromal Phase of Migraine - Part 1

2025-11-1103:01

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 2

2025-11-1002:16

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1

2025-11-0704:05

Neurotoxicity Imaging in Children and Young Adults After CAR T-Cell Therapy for B-Cell Malignancies

2025-11-0604:04

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 3

2025-11-0504:00

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 2

2025-11-0403:47

00:00

Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)

American Academy of Neurology

#box-pro-ellipsis-176462907687993{-webkit-line-clamp:2;}Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)

Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)

American Academy of Neurology

Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)